E Fund Management Co. Ltd. Increases Holdings in Moderna, Inc. (NASDAQ:MRNA)

E Fund Management Co. Ltd. raised its holdings in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 35.0% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 30,592 shares of the company's stock after purchasing an additional 7,939 shares during the period. E Fund Management Co. Ltd.'s holdings in Moderna were worth $1,272,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Raymond James Financial Inc. purchased a new stake in shares of Moderna during the fourth quarter valued at $8,493,000. Arizona State Retirement System grew its stake in Moderna by 1.5% during the 4th quarter. Arizona State Retirement System now owns 94,859 shares of the company's stock valued at $3,944,000 after purchasing an additional 1,446 shares during the last quarter. Proficio Capital Partners LLC increased its holdings in shares of Moderna by 4,418.9% in the fourth quarter. Proficio Capital Partners LLC now owns 147,360 shares of the company's stock valued at $6,127,000 after purchasing an additional 144,099 shares during the period. M&T Bank Corp lifted its holdings in shares of Moderna by 10.1% during the fourth quarter. M&T Bank Corp now owns 17,759 shares of the company's stock worth $739,000 after purchasing an additional 1,622 shares during the period. Finally, Commerzbank Aktiengesellschaft FI boosted its position in Moderna by 101.4% in the fourth quarter. Commerzbank Aktiengesellschaft FI now owns 12,261 shares of the company's stock valued at $483,000 after buying an additional 6,174 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

Several brokerages have commented on MRNA. Morgan Stanley decreased their price objective on shares of Moderna from $70.00 to $38.00 and set an "equal weight" rating for the company in a research note on Wednesday, January 15th. Royal Bank of Canada restated a "sector perform" rating and set a $40.00 target price on shares of Moderna in a research report on Tuesday, February 18th. Leerink Partners cut their price target on Moderna from $31.00 to $27.00 and set an "underweight" rating on the stock in a research report on Thursday, January 16th. Barclays cut Moderna from an "overweight" rating to an "equal weight" rating and decreased their price objective for the company from $111.00 to $45.00 in a report on Tuesday, February 18th. Finally, UBS Group dropped their target price on Moderna from $96.00 to $78.00 and set a "buy" rating on the stock in a report on Wednesday, February 19th. Four equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $60.63.

Moderna Price Performance

NASDAQ MRNA traded down $2.20 during mid-day trading on Tuesday, hitting $33.76. The stock had a trading volume of 12,399,214 shares, compared to its average volume of 12,684,797. The firm's 50 day moving average is $36.53 and its 200 day moving average is $48.45. The stock has a market capitalization of $13.03 billion, a price-to-earnings ratio of -3.64 and a beta of 1.86. Moderna, Inc. has a twelve month low of $29.25 and a twelve month high of $170.47.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.